NewAmsterdam Pharma's cholesterol drug combination met key goals in a late-stage study, leading to plans for regulatory approval. The Phase 3 trial showed significant reduction in LDL cholesterol in adults with certain conditions. Regulatory filings will be pursued globally. Trading of NewAmsterdam shares was halted.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing